Linked Data API

Show Search Form

Search Results

155934
registered interest false more like this
date less than 2014-11-17more like thismore than 2014-11-17
answering body
Department of Health more like this
answering dept id 17 remove filter
answering dept short name Health more like this
answering dept sort name Health more like this
hansard heading Monitor more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, when he expects to appoint a permanent chair of Monitor. more like this
tabling member constituency Copeland more like this
tabling member printed
Mr Jamie Reed more like this
uin 214806 more like this
answer
answer
is ministerial correction false more like this
date of answer remove maximum value filtermore like thismore than 2014-11-20
answer text <p>Baroness Hanham’s appointment as Chair continues until 31 March 2016. A further recruitment process will take place towards the end of 2015.</p><p> </p> more like this
answering member constituency North Norfolk more like this
answering member printed Norman Lamb more like this
question first answered
less than 2014-11-20T17:04:25.147Zmore like thismore than 2014-11-20T17:04:25.147Z
answering member
1439
label Biography information for Norman Lamb more like this
tabling member
1503
label Biography information for Mr Jamie Reed more like this
155935
registered interest false more like this
date less than 2014-11-17more like thismore than 2014-11-17
answering body
Department of Health more like this
answering dept id 17 remove filter
answering dept short name Health more like this
answering dept sort name Health more like this
hansard heading Clinical Trials more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, how many patients were recruited to participate in a phase (a) I, (b) II, (c) III and (d) IV clinical trial in each of the last five years. more like this
tabling member constituency Liverpool, Wavertree more like this
tabling member printed
Luciana Berger more like this
uin 214789 more like this
answer
answer
is ministerial correction false more like this
date of answer remove maximum value filtermore like thismore than 2014-11-20
answer text <p>Data is not available on the total number of patients recruited to participate in a clinical trial. Recruitment in England to clinical trials hosted by the National Institute for Health Research (NIHR) Clinical Research Network (CRN), and total recruitment in England to all trials and other well-designed studies hosted by the CRN is shown in the following table.</p><p> </p><p> </p><p> </p><table><tbody><tr><td><p> </p></td><td><p>2009-10</p></td><td><p>2010-11</p></td><td><p>2011-12</p></td><td><p>2012-13</p></td><td><p>2013-14</p></td></tr><tr><td><p>Phase I</p></td><td><p>70</p></td><td><p>85</p></td><td><p>151</p></td><td><p>5,363</p></td><td><p>931</p></td></tr><tr><td><p>Phase I/II</p></td><td><p>283</p></td><td><p>305</p></td><td><p>808</p></td><td><p>185</p></td><td><p>279</p></td></tr><tr><td><p>Phase II</p></td><td><p>3,874</p></td><td><p>2,268</p></td><td><p>2,913</p></td><td><p>3,306</p></td><td><p>3,234</p></td></tr><tr><td><p>Phase II/III</p></td><td><p>2,729</p></td><td><p>2,578</p></td><td><p>3,041</p></td><td><p>2,517</p></td><td><p>3,237</p></td></tr><tr><td><p>Phase III</p></td><td><p>31,363</p></td><td><p>33,027</p></td><td><p>33,812</p></td><td><p>35,140</p></td><td><p>28,595</p></td></tr><tr><td><p>Phase IV</p></td><td><p>11,077</p></td><td><p>10,876</p></td><td><p>8,647</p></td><td><p>9,944</p></td><td><p>23,780</p></td></tr><tr><td><p>Total (trials)</p></td><td><p>49,396</p></td><td><p>49,139</p></td><td><p>49,372</p></td><td><p>56,455</p></td><td><p>60,056</p></td></tr><tr><td><p>All trials and studies</p></td><td><p>454,138</p></td><td><p>564,698</p></td><td><p>595,540</p></td><td><p>637,974</p></td><td><p>604,216</p></td></tr></tbody></table><p> </p><p> </p><p> </p><p>Recruitment in England to clinical trials hosted by NIHR-designated infrastructure for experimental medicine including NIHR biomedical research centres, NIHR biomedical research units, and NIHR clinical research facilities for experimental medicine (from 2012-13 onwards), is shown in the following table.</p><p> </p><p><strong> </strong></p><p> </p><table><tbody><tr><td><p> </p></td><td><p>2009-10</p></td><td><p>2010-11</p></td><td><p>2011-12</p></td><td><p>2012-13</p></td><td><p>2013-14</p></td></tr><tr><td><p>Phase 0</p></td><td><p>0</p></td><td><p>530</p></td><td><p>1,275</p></td><td><p>255</p></td><td><p>1,046</p></td></tr><tr><td><p>Phase I</p></td><td><p>2,185</p></td><td><p>2,178</p></td><td><p>2,471</p></td><td><p>2,827</p></td><td><p>4,390</p></td></tr><tr><td><p>Phase II</p></td><td><p>5,423</p></td><td><p>3,923</p></td><td><p>3,169</p></td><td><p>8,467</p></td><td><p>7,893</p></td></tr><tr><td><p>Phase III</p></td><td><p>5,003</p></td><td><p>5,228</p></td><td><p>7,276</p></td><td><p>8,930</p></td><td><p>n/a</p></td></tr><tr><td><p>Phase IV</p></td><td><p>2,425</p></td><td><p>23,519</p></td><td><p>1,843</p></td><td><p>3,135</p></td><td><p>n/a</p></td></tr><tr><td><p>Total trials</p></td><td><p>15,037</p></td><td><p>35,378</p></td><td><p>16,034</p></td><td><p>23,614</p></td><td><p>n/a</p></td></tr></tbody></table><p> </p><p><strong> </strong></p><p> </p>
answering member constituency Mid Norfolk more like this
answering member printed George Freeman more like this
question first answered
less than 2014-11-20T17:12:10.68Zmore like thismore than 2014-11-20T17:12:10.68Z
answering member
4020
label Biography information for George Freeman more like this
tabling member
4036
label Biography information for Luciana Berger more like this
155936
registered interest false more like this
date less than 2014-11-17more like thismore than 2014-11-17
answering body
Department of Health more like this
answering dept id 17 remove filter
answering dept short name Health more like this
answering dept sort name Health more like this
hansard heading Vaccination more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, pursuant to the Answer of 17 November 2014 to Question 214322, what alternative vaccines are available that do not contain porcine gelatine for people who observe religions that restrict the consumption of pork products. more like this
tabling member constituency Liverpool, Wavertree more like this
tabling member printed
Luciana Berger more like this
uin 214790 more like this
answer
answer
is ministerial correction false more like this
date of answer remove maximum value filtermore like thismore than 2014-11-20
answer text <p>A number of vaccines contain porcine gelatine, which is used to stabilise live viral vaccines and is contained in many pharmaceutical products. The vaccines used in the national immunisation programme which contain porcine gelatine are Fluenz®, measles, mumps and rubella (MMR) VaxPro® and Zostavax®.</p><p> </p><p> </p><p> </p><p>Fluenz® is used to immunise children against flu. It is a live attenuated vaccine which is administered by means of a nasal spray. There is no equivalent appropriate alternative which offers the same degree of protection, nor is there any other live attenuated vaccine available in Europe.</p><p> </p><p> </p><p> </p><p>MMR VaxPro® is used to immunise against MMR. There is an alternative vaccine, Priorix®, which does not contain porcine gelatine and offers equivalent protection.</p><p> </p><p> </p><p> </p><p>Zostavax® is used to immunise adults against shingles. There is no alternative vaccine licensed for use in the United Kingdom.</p><p> </p><p><strong> </strong></p><p> </p><p>Public Health England (PHE) has gained broad acceptance from faith groups for the use of porcine gelatine in non-oral medicines and more information can be found at PHE’s website:</p><p> </p><p> </p><p> </p><p><a href="http://www.gov.uk/government/news/vaccines-and-gelatine-phe-response" target="_blank">www.gov.uk/government/news/vaccines-and-gelatine-phe-response</a></p><p> </p><p> </p><p> </p>
answering member constituency Battersea more like this
answering member printed Jane Ellison more like this
question first answered
less than 2014-11-20T14:34:30.993Zmore like thismore than 2014-11-20T14:34:30.993Z
answering member
3918
label Biography information for Jane Ellison more like this
tabling member
4036
label Biography information for Luciana Berger more like this
155937
registered interest false more like this
date less than 2014-11-17more like thismore than 2014-11-17
answering body
Department of Health more like this
answering dept id 17 remove filter
answering dept short name Health more like this
answering dept sort name Health more like this
hansard heading Ovarian Cancer more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, what assessment he has made of the effectiveness of the implementation of the National Institute for Health and Care Excellence's most recent guidelines for genetic testing for ovarian cancer. more like this
tabling member constituency South Down more like this
tabling member printed
Ms Margaret Ritchie more like this
uin 214812 more like this
answer
answer
is ministerial correction false more like this
date of answer remove maximum value filtermore like thismore than 2014-11-20
answer text <p>The National Institute for Health and Care Excellence’s clinical guideline on familial breast cancer, published in June 2013, recommends that women with breast or ovarian cancer should be offered genetic testing if their combined BRCA1 and BRCA2 mutation carrier possibility is 10% or more.</p><p> </p><p> </p><p> </p><p>NHS England is considering moving to a lower threshold as part of the annual prioritisation process for funding in 2015-16.</p><p> </p><p><strong> </strong></p><p> </p><p>We intend to raise the matter of genetic testing for ovarian cancer patients with the Health Ministers of Scotland, Wales, and Northern Ireland in our next regular meeting with them.</p><p> </p><p> </p><p> </p><p> </p><p> </p> more like this
answering member constituency Battersea more like this
answering member printed Jane Ellison more like this
grouped question UIN 214783 more like this
question first answered
less than 2014-11-20T16:50:39.107Zmore like thismore than 2014-11-20T16:50:39.107Z
answering member
3918
label Biography information for Jane Ellison more like this
tabling member
4130
label Biography information for Baroness Ritchie of Downpatrick more like this
155938
registered interest false more like this
date less than 2014-11-17more like thismore than 2014-11-17
answering body
Department of Health more like this
answering dept id 17 remove filter
answering dept short name Health more like this
answering dept sort name Health more like this
hansard heading Ovarian Cancer: Northern Ireland more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, what discussions he has had with the Health Minister in Northern Ireland regarding the implementation of the most recent National Institute for Health and Care Excellence's guidelines for genetic testing for ovarian cancer. more like this
tabling member constituency South Down more like this
tabling member printed
Ms Margaret Ritchie more like this
uin 214783 more like this
answer
answer
is ministerial correction false more like this
date of answer remove maximum value filtermore like thismore than 2014-11-20
answer text <p>The National Institute for Health and Care Excellence’s clinical guideline on familial breast cancer, published in June 2013, recommends that women with breast or ovarian cancer should be offered genetic testing if their combined BRCA1 and BRCA2 mutation carrier possibility is 10% or more.</p><p> </p><p> </p><p> </p><p>NHS England is considering moving to a lower threshold as part of the annual prioritisation process for funding in 2015-16.</p><p> </p><p><strong> </strong></p><p> </p><p>We intend to raise the matter of genetic testing for ovarian cancer patients with the Health Ministers of Scotland, Wales, and Northern Ireland in our next regular meeting with them.</p><p> </p><p> </p><p> </p><p> </p><p> </p> more like this
answering member constituency Battersea more like this
answering member printed Jane Ellison more like this
grouped question UIN 214812 more like this
question first answered
less than 2014-11-20T16:50:39.217Zmore like thismore than 2014-11-20T16:50:39.217Z
answering member
3918
label Biography information for Jane Ellison more like this
tabling member
4130
label Biography information for Baroness Ritchie of Downpatrick more like this
155939
registered interest false more like this
date less than 2014-11-17more like thismore than 2014-11-17
answering body
Department of Health more like this
answering dept id 17 remove filter
answering dept short name Health more like this
answering dept sort name Health more like this
hansard heading Prostate Cancer more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, following the publication of the results of the ProtecT trial on localised prostate cancer diagnosis, what changes in diagnosis will be introduced for men aged between 50 and 69. more like this
tabling member constituency East Londonderry more like this
tabling member printed
Mr Gregory Campbell more like this
uin 214793 more like this
answer
answer
is ministerial correction false more like this
date of answer remove maximum value filtermore like thismore than 2014-11-20
answer text <p>As the main aim of the ProtecT trial (Prostate testing for cancer and Treatment) is assessing mortality after 10 year follow-up, the full results of the trial are not expected to be known until 2017. Assessments on the impact of the results on changes to diagnosis will be made based on these results.</p><p> </p> more like this
answering member constituency Battersea more like this
answering member printed Jane Ellison more like this
question first answered
less than 2014-11-20T15:04:00.977Zmore like thismore than 2014-11-20T15:04:00.977Z
answering member
3918
label Biography information for Jane Ellison more like this
tabling member
1409
label Biography information for Mr Gregory Campbell more like this
155940
registered interest false more like this
date less than 2014-11-17more like thismore than 2014-11-17
answering body
Department of Health more like this
answering dept id 17 remove filter
answering dept short name Health more like this
answering dept sort name Health more like this
hansard heading Brain: Tumours more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, pursuant to the Answer of 7 November 2014 to Question 213360, which of the centres reviewed support the running of a seven-day service. more like this
tabling member constituency Wells more like this
tabling member printed
Tessa Munt more like this
uin 214504 more like this
answer
answer
is ministerial correction false more like this
date of answer remove maximum value filtermore like thismore than 2014-11-20
answer text <p>The proposal of a seven-day service is part of NHS England's consultation on the future configuration of services for stereotactic radiosurgery which closes on 26 January 2015. Providers are encouraged to input into the consultation process through:</p><p> </p><p> </p><p> </p><p><a href="http://www.engage.england.nhs.uk/survey/options-for-change" target="_blank">http://www.engage.england.nhs.uk/survey/options-for-change</a></p><p> </p><p> </p><p> </p><p>As a result of consultation feedback, NHS England will make the decision whether to procure a seven-day service. At this point providers can consider whether they wish to offer a service on this basis.</p><p> </p><p> </p><p> </p><p>Attendees of the stereotactic radiosurgery and radiotherapy focus group meeting who are members of the Clinical Reference Groups (CRG) were as follows:</p><p> </p><p> </p><p> </p><p>21 March 2014</p><p> </p><p>Bob Bradford – Adult Neurosurgery CRG</p><p> </p><p>Adrian Crellin – Radiotherapy CRG</p><p> </p><p>Peter Enevoldson – Neurosciences CRG</p><p> </p><p>Paul Grundy – Brain and CNS CRG</p><p> </p><p>Richard Grunewald – Neurosciences CRG</p><p> </p><p>Neil Kitchen – Stereotactic Radiosurgery CRG</p><p> </p><p>Catherine McBain – Brain and CNS CRG</p><p> </p><p>Paul May – Adult Neurosurgery CRG</p><p> </p><p>Matt Radatz – Stereotactic Radiosurgery CRG</p><p> </p><p>Nick Slevin – Radiotherapy CRG</p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p>23 May 2014</p><p> </p><p>Adrian Crellin – Radiotherapy CRG</p><p> </p><p>Neil Kitchen – Stereotactic Radiosurgery CRG</p><p> </p><p>Paul May – Adult Neurosurgery CRG</p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p>
answering member constituency Battersea more like this
answering member printed Jane Ellison more like this
grouped question UIN
214501 more like this
214505 more like this
question first answered
less than 2014-11-20T16:41:50.937Zmore like thismore than 2014-11-20T16:41:50.937Z
answering member
3918
label Biography information for Jane Ellison more like this
tabling member
4089
label Biography information for Tessa Munt more like this
155941
registered interest false more like this
date less than 2014-11-17more like thismore than 2014-11-17
answering body
Department of Health more like this
answering dept id 17 remove filter
answering dept short name Health more like this
answering dept sort name Health more like this
hansard heading Radiotherapy more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, pursuant to the Answer of 7 November 2014 to Question 213582, what costs were identified by the Walton Centre NHS Trust for treating patients (a) surgically and (b) with stereotactic radiotherapy/stereotactic radiosurgery. more like this
tabling member constituency Wells more like this
tabling member printed
Tessa Munt more like this
uin 214505 more like this
answer
answer
is ministerial correction false more like this
date of answer remove maximum value filtermore like thismore than 2014-11-20
answer text <p>The proposal of a seven-day service is part of NHS England's consultation on the future configuration of services for stereotactic radiosurgery which closes on 26 January 2015. Providers are encouraged to input into the consultation process through:</p><p> </p><p> </p><p> </p><p><a href="http://www.engage.england.nhs.uk/survey/options-for-change" target="_blank">http://www.engage.england.nhs.uk/survey/options-for-change</a></p><p> </p><p> </p><p> </p><p>As a result of consultation feedback, NHS England will make the decision whether to procure a seven-day service. At this point providers can consider whether they wish to offer a service on this basis.</p><p> </p><p> </p><p> </p><p>Attendees of the stereotactic radiosurgery and radiotherapy focus group meeting who are members of the Clinical Reference Groups (CRG) were as follows:</p><p> </p><p> </p><p> </p><p>21 March 2014</p><p> </p><p>Bob Bradford – Adult Neurosurgery CRG</p><p> </p><p>Adrian Crellin – Radiotherapy CRG</p><p> </p><p>Peter Enevoldson – Neurosciences CRG</p><p> </p><p>Paul Grundy – Brain and CNS CRG</p><p> </p><p>Richard Grunewald – Neurosciences CRG</p><p> </p><p>Neil Kitchen – Stereotactic Radiosurgery CRG</p><p> </p><p>Catherine McBain – Brain and CNS CRG</p><p> </p><p>Paul May – Adult Neurosurgery CRG</p><p> </p><p>Matt Radatz – Stereotactic Radiosurgery CRG</p><p> </p><p>Nick Slevin – Radiotherapy CRG</p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p>23 May 2014</p><p> </p><p>Adrian Crellin – Radiotherapy CRG</p><p> </p><p>Neil Kitchen – Stereotactic Radiosurgery CRG</p><p> </p><p>Paul May – Adult Neurosurgery CRG</p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p>
answering member constituency Battersea more like this
answering member printed Jane Ellison more like this
grouped question UIN
214501 more like this
214504 more like this
question first answered
less than 2014-11-20T16:41:51.25Zmore like thismore than 2014-11-20T16:41:51.25Z
answering member
3918
label Biography information for Jane Ellison more like this
tabling member
4089
label Biography information for Tessa Munt more like this
155947
registered interest false more like this
date less than 2014-11-17more like thismore than 2014-11-17
answering body
Department of Health more like this
answering dept id 17 remove filter
answering dept short name Health more like this
answering dept sort name Health more like this
hansard heading Radiotherapy: Clinical Reference Groups more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, pursuant to the Answer of 10 November 2014 to Question 213582, if he will publish the names of those members who attended each of the two focus groups on behalf of the Radiotherapy Clinical Reference Group (CRG), the Adult Neurosurgery CRG, the Brain and Central Nervous System CRG, the Neurosciences CRG and the Stereotactic Radiosurgery CRG. more like this
tabling member constituency Wells more like this
tabling member printed
Tessa Munt more like this
uin 214501 more like this
answer
answer
is ministerial correction false more like this
date of answer remove maximum value filtermore like thismore than 2014-11-20
answer text <p>The proposal of a seven-day service is part of NHS England's consultation on the future configuration of services for stereotactic radiosurgery which closes on 26 January 2015. Providers are encouraged to input into the consultation process through:</p><p> </p><p> </p><p> </p><p><a href="http://www.engage.england.nhs.uk/survey/options-for-change" target="_blank">http://www.engage.england.nhs.uk/survey/options-for-change</a></p><p> </p><p> </p><p> </p><p>As a result of consultation feedback, NHS England will make the decision whether to procure a seven-day service. At this point providers can consider whether they wish to offer a service on this basis.</p><p> </p><p> </p><p> </p><p>Attendees of the stereotactic radiosurgery and radiotherapy focus group meeting who are members of the Clinical Reference Groups (CRG) were as follows:</p><p> </p><p> </p><p> </p><p>21 March 2014</p><p> </p><p>Bob Bradford – Adult Neurosurgery CRG</p><p> </p><p>Adrian Crellin – Radiotherapy CRG</p><p> </p><p>Peter Enevoldson – Neurosciences CRG</p><p> </p><p>Paul Grundy – Brain and CNS CRG</p><p> </p><p>Richard Grunewald – Neurosciences CRG</p><p> </p><p>Neil Kitchen – Stereotactic Radiosurgery CRG</p><p> </p><p>Catherine McBain – Brain and CNS CRG</p><p> </p><p>Paul May – Adult Neurosurgery CRG</p><p> </p><p>Matt Radatz – Stereotactic Radiosurgery CRG</p><p> </p><p>Nick Slevin – Radiotherapy CRG</p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p>23 May 2014</p><p> </p><p>Adrian Crellin – Radiotherapy CRG</p><p> </p><p>Neil Kitchen – Stereotactic Radiosurgery CRG</p><p> </p><p>Paul May – Adult Neurosurgery CRG</p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p>
answering member constituency Battersea more like this
answering member printed Jane Ellison more like this
grouped question UIN
214504 more like this
214505 more like this
question first answered
less than 2014-11-20T16:41:51.093Zmore like thismore than 2014-11-20T16:41:51.093Z
answering member
3918
label Biography information for Jane Ellison more like this
tabling member
4089
label Biography information for Tessa Munt more like this
155949
registered interest false more like this
date less than 2014-11-17more like thismore than 2014-11-17
answering body
Department of Health more like this
answering dept id 17 remove filter
answering dept short name Health more like this
answering dept sort name Health more like this
hansard heading Cancer Drugs Fund more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, pursuant to the Answer of 7 November 2014 to Question 213358, from which of NHS England's underspent budgets amounts were taken to meet the overspend of £30,539,000; and how much was so taken in each case. more like this
tabling member constituency Wells more like this
tabling member printed
Tessa Munt more like this
uin 214503 more like this
answer
answer
is ministerial correction false more like this
date of answer remove maximum value filtermore like thismore than 2014-11-20
answer text <p>NHS England has advised that the overspend on the Cancer Drugs Fund in 2013-14</p><p> </p><p>was managed as part of its routine financial management process. The overspend represented less than 0.05% of NHS England’s total budget for that year.</p><p> </p><p> </p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p> more like this
answering member constituency Mid Norfolk more like this
answering member printed George Freeman more like this
question first answered
less than 2014-11-20T17:14:40.993Zmore like thismore than 2014-11-20T17:14:40.993Z
answering member
4020
label Biography information for George Freeman more like this
tabling member
4089
label Biography information for Tessa Munt more like this